Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain
NCT ID: NCT01458015
Last Updated: 2025-01-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
3 participants
INTERVENTIONAL
2011-10-31
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.
NCT01838616
Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models
NCT01615510
Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin
NCT01352741
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
NCT01063868
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
NCT00983385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
oxycodone
tapentadol, oxycodone
tapentadol pr 100-500 mg oxycodone cr 20-120mg
tapentadol
tapentadol, oxycodone
tapentadol pr 100-500 mg oxycodone cr 20-120mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tapentadol, oxycodone
tapentadol pr 100-500 mg oxycodone cr 20-120mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic neuropathic pain (NRS =\> 6)
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Schleswig-Holstein
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ralf Baron
Prof. Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ralf Baron, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Head of Unit of Neuropathic Pain Research and Therapy, Department of Neurology, University Clinic Kiel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division for Neurological Pain Research and Therapy
Kiel, Schleswig-Holstein, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TapOxy01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.